Skip to main content
Premium Trial:

Request an Annual Quote

GeneTraffic, JMV 1.0, BioCoRE, GeneCards 2.25, UDB 25


Iobion of San Diego has released version 2.0 of its GeneTraffic microarray data management and analysis software. The new release offers “start to finish” data analysis capability, according to Stephen Sharp, director of marketing. Users can import numerical two-color data files as well as image files from any scanner and move from data validation to graphical data representation and manipulation to cluster analysis, he said. GeneTraffic 2.0 uses graphical ActiveX components built on the OpenGL framework, which the company described as “a significant addition” to the software’s present web-based graphics capabilities.

The Theoretical Biophysics Group at the University of Illinois has released JMV 1.0, a Java-based molecular viewer, as part of BioCoRE (Biological Collaborative Research Environment), a freely accessible web-based collaboratory for biomedical research and training ( JMV is available at In addition, several other BioCoRE components have been updated.


The Weizmann Institute of Israel has released GeneCards 2.25 and UDB (Unified Database) 25 through its website,

Filed under

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.